June 01, 2020 New analysis confirms that multiple myeloma patients in the OCEAN study stay on treatment longer than previously estimated – results expected H1-2021
May 29, 2020 LifeArc awards £ 1.5 million grant to Vicore Pharma for the VP01 COVID-19 clinical study
May 28, 2020 Oncopeptides reinitiates patient enrollment to the melflufen clinical program following a temporary pause due to the COVID-19 pandemic
May 22, 2020 Oncopeptides completes enrollment to the pivotal phase 3 study OCEAN for relapsed refractory multiple myeloma – 450 patients included